Rapport Therapeutics, Inc. RAPP Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s total equity?
- Rapport Therapeutics, Inc. (RAPP) reported total equity of $471.51M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s total equity changed year-over-year?
- Rapport Therapeutics, Inc.'s total equity increased by 65.0% year-over-year, from $285.84M to $471.51M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s total equity?
- Over 3 years (2022 to 2025), Rapport Therapeutics, Inc.'s total equity has grown at a 263.8% compound annual growth rate (CAGR), from -$10.06M to $484.65M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.